CA3021932C - Utilisation d'histidinate de chrome pour le traitement de troubles cardiometaboliques - Google Patents

Utilisation d'histidinate de chrome pour le traitement de troubles cardiometaboliques Download PDF

Info

Publication number
CA3021932C
CA3021932C CA3021932A CA3021932A CA3021932C CA 3021932 C CA3021932 C CA 3021932C CA 3021932 A CA3021932 A CA 3021932A CA 3021932 A CA3021932 A CA 3021932A CA 3021932 C CA3021932 C CA 3021932C
Authority
CA
Canada
Prior art keywords
chromium
subject
levels
disease
cholesterol
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3021932A
Other languages
English (en)
Other versions
CA3021932A1 (fr
Inventor
Vijaya Juturu
James Komorowski
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nutrition 21 LLC
Original Assignee
JDS Therapeutics LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by JDS Therapeutics LLC filed Critical JDS Therapeutics LLC
Publication of CA3021932A1 publication Critical patent/CA3021932A1/fr
Application granted granted Critical
Publication of CA3021932C publication Critical patent/CA3021932C/fr
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Des procédés sont décrits permettant de traiter, de prévenir et daméliorer des affections associées avec le syndrome cardiométabolique, en identifiant un sujet nécessitant un traitement, une protection ou une amélioration dune affection associée avec le syndrome cardiométabolique, et permettant dapporter au sujet une quantité thérapeutiquement efficace dune composition comprenant un complexe à base de chrome à action rapide et un complexe à base de chrome à action lente.
CA3021932A 2007-01-31 2008-01-29 Utilisation d'histidinate de chrome pour le traitement de troubles cardiometaboliques Active CA3021932C (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US88756107P 2007-01-31 2007-01-31
US60/887561 2007-01-31
CA2931881A CA2931881C (fr) 2007-01-31 2008-01-29 Utilisation d'histidinate de chrome pour le traitement de troubles cardiometaboliques

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CA2931881A Division CA2931881C (fr) 2007-01-31 2008-01-29 Utilisation d'histidinate de chrome pour le traitement de troubles cardiometaboliques

Publications (2)

Publication Number Publication Date
CA3021932A1 CA3021932A1 (fr) 2008-08-07
CA3021932C true CA3021932C (fr) 2020-12-15

Family

ID=39674481

Family Applications (3)

Application Number Title Priority Date Filing Date
CA2676977A Active CA2676977C (fr) 2007-01-31 2008-01-29 Utilisation d'histidinate de chrome pour le traitement de troubles cardiometaboliques
CA2931881A Active CA2931881C (fr) 2007-01-31 2008-01-29 Utilisation d'histidinate de chrome pour le traitement de troubles cardiometaboliques
CA3021932A Active CA3021932C (fr) 2007-01-31 2008-01-29 Utilisation d'histidinate de chrome pour le traitement de troubles cardiometaboliques

Family Applications Before (2)

Application Number Title Priority Date Filing Date
CA2676977A Active CA2676977C (fr) 2007-01-31 2008-01-29 Utilisation d'histidinate de chrome pour le traitement de troubles cardiometaboliques
CA2931881A Active CA2931881C (fr) 2007-01-31 2008-01-29 Utilisation d'histidinate de chrome pour le traitement de troubles cardiometaboliques

Country Status (6)

Country Link
US (4) US20100009015A1 (fr)
EP (1) EP2120930A4 (fr)
AU (1) AU2008210586B2 (fr)
CA (3) CA2676977C (fr)
MX (1) MX2009008135A (fr)
WO (1) WO2008094939A1 (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3050568B1 (fr) 2007-03-13 2020-12-02 JDS Therapeutics, LLC Procédés et compositions pour la libération prolongée de chrome
WO2009002867A2 (fr) 2007-06-26 2008-12-31 Nutrition 21, Inc. Forme posologique à unités multiples contenant un agent thérapeutique en combinaison avec un complément alimentaire
EP3513790A1 (fr) * 2009-07-01 2019-07-24 JDS Therapeutics, LLC Complexes de chrome en tant qu'activateurs de transporteurs de glucose dans le cerveau
ES2927800T3 (es) 2011-03-01 2022-11-11 Nutrition 21 Llc Composición de insulina y cromo para el tratamiento y la prevención de diabetes, hipoglicemia y trastornos relacionados
US20130110531A1 (en) * 2011-10-29 2013-05-02 Kenneth O Russell Method for reducing healthcare costs
WO2016209812A1 (fr) * 2015-06-23 2016-12-29 Jds Therapeutics, Llc Complexes d'histidinate de chrome et de picolinate de chrome
GB2564295A (en) 2016-02-11 2019-01-09 Nutrition 21 Llc Chromium containing compositions for improving health and fitness
US20190183928A1 (en) * 2016-08-08 2019-06-20 Glucare Llc Pharmaceutical compositions comprising chromium and carbohydrate blockers
US20200360305A1 (en) 2017-12-01 2020-11-19 INSERM (Institut National de la Ssnté et de la Researche Médecale) Use of triethylenetetramine (teta) for the therapeutic induction of autophagy
WO2019238934A1 (fr) 2018-06-15 2019-12-19 INSERM (Institut National de la Santé et de la Recherche Médicale) Utilisation de l'apolipoprotéine m pour le traitement et le diagnostic de la résistance à l'insuline
WO2020172262A1 (fr) * 2019-02-19 2020-08-27 James Janine Composition à base de chrome et procédés associés
EP4309733A1 (fr) 2022-07-22 2024-01-24 Institut National de la Santé et de la Recherche Médicale (INSERM) Neutralisation de la protéine de liaison à l'acyl-coa pour le traitement d'un dysfonctionnement cardiaque

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3065342D1 (en) * 1979-03-19 1983-11-24 Procter & Gamble Chromium acetylacetonate as a dietary supplement and pharmaceutical agent
US4315927A (en) * 1980-08-08 1982-02-16 The United States Of America As Represented By The Secretary Of Agriculture Dietary supplementation with essential metal picolinates
USRE33988E (en) * 1980-08-08 1992-07-07 The United States of America as repesented by the Secretary of Agriculture Dietary supplementation with essential metal picolinates
US5194615A (en) * 1983-07-08 1993-03-16 The William Seroy Group Synthetic GTF chromium nicotinate material and its preparation
US4954492A (en) * 1983-07-08 1990-09-04 The William Seroy Group Synthetic GTF chromium material for decreasing blood lipid levels and process therefor
US5087623A (en) * 1988-05-31 1992-02-11 Nitrition 21 Chromic picolinate treatment
US5175156A (en) * 1987-11-30 1992-12-29 Nutrition 21 Chromic picolinate treatment
US6140304A (en) * 1988-09-28 2000-10-31 Eicotech Corporation Method of and nutritional and pharmaceutical compositions for reduction of hyperinsulinemia
US5087624A (en) * 1989-03-21 1992-02-11 Nutrition 21 Chromic picolinate treatment
US5614553A (en) * 1990-07-06 1997-03-25 Albion Laboratories, Inc. Composition and method for alleviating stress in warm-blooded animals
US5164384A (en) * 1991-06-19 1992-11-17 Metagenics, Inc. Anabolic mineral formula
US5336672A (en) * 1992-07-21 1994-08-09 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Increasing egg production in poultry
SE9203753D0 (sv) * 1992-12-11 1992-12-11 Kabi Pharmacia Ab Expression system for producing apolipoprotein ai-m
US5496827A (en) * 1994-07-15 1996-03-05 Patrick; Jay Compositions for the transdermal delivery of nutrients
US6329361B1 (en) * 1995-05-12 2001-12-11 Nutrition 21 High-dose chromic picolinate treatment of type II diabetes
US5597585A (en) * 1995-12-26 1997-01-28 Williams; Andrew H. Vitamin/mineral composition
US5635535A (en) * 1996-04-05 1997-06-03 Wagstaff; Robert K. Method for increasing blood glucose levels
US5789401A (en) * 1997-08-08 1998-08-04 Nutrition 21 High-dose chromium/biotin treatment of type II diabetes
AU751431B2 (en) * 1997-08-08 2002-08-15 Nutrition 21 Chromium/biotin treatment of type II diabetes
US6037323A (en) * 1997-09-29 2000-03-14 Jean-Louis Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en) * 1997-09-29 1999-12-21 J. L. Dasseux Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6048846A (en) * 1998-02-26 2000-04-11 Cochran; Timothy M. Compositions used in human treatment
US5948772A (en) * 1998-08-28 1999-09-07 Ambi Inc. Chromium picolinate compositions and uses thereof
US6376549B1 (en) * 1998-09-17 2002-04-23 Akesis Pharmaceuticals, Inc. Metforimin-containing compositions for the treatment of diabetes
US6689383B1 (en) * 1999-10-08 2004-02-10 The United States Of America As Represented By The Secretary Of Agriculture Chromium-histidine complexes as nutrient supplements
CN1665566A (zh) * 2000-09-21 2005-09-07 营养21公司 用铬络合物、共轭脂肪酸和 /或共轭脂肪醇治疗糖尿病、减少身体脂肪、改善胰岛素敏感性、缓解高血糖症和高胆固醇血症的方法和组合物
WO2002036202A2 (fr) * 2000-11-02 2002-05-10 Nutrition 21, Inc. Procedes et compositions permettant d'ameliorer la sensibilite insulinique, de reduire l'hyperglycemie, et de reduire l'hypercholesterolemie a l'aide de complexes de chrome et d'acide alphalipoique
DE60214849T2 (de) * 2001-02-27 2007-04-26 Nutrition 21, Inc. Chromium/biotin behandlung von dyslipidämie
AU2003226313A1 (en) * 2002-04-23 2003-11-10 Nutrition 21, Inc. Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
US7063865B2 (en) * 2002-05-10 2006-06-20 Jeremy Park Jones Composition and method for substantially reducing the deleterious effects of alcohol on the body
US20040005368A1 (en) * 2002-07-01 2004-01-08 Morris Mann Novel approach to weight loss comprising a modified protein composition that regulates blood sugar in conjunction with compositions that increase oxygen uptake and suppress appetite
US20050069593A1 (en) * 2003-09-29 2005-03-31 Life Time Fitness, Inc. Nutritional supplement containing 7-Keto-DHEA and conjugated linoleic acid
US20060024383A1 (en) * 2004-07-27 2006-02-02 Roger Berlin Compositions containing policosanol and chromium and/or chromium salts and their pharmaceutical uses
EP3050568B1 (fr) * 2007-03-13 2020-12-02 JDS Therapeutics, LLC Procédés et compositions pour la libération prolongée de chrome

Also Published As

Publication number Publication date
CA2931881C (fr) 2018-12-11
EP2120930A1 (fr) 2009-11-25
CA3021932A1 (fr) 2008-08-07
AU2008210586B2 (en) 2013-07-04
US20220023337A1 (en) 2022-01-27
EP2120930A4 (fr) 2012-12-05
MX2009008135A (es) 2009-08-12
CA2676977A1 (fr) 2008-08-07
AU2008210586A1 (en) 2008-08-07
CA2931881A1 (fr) 2008-08-07
WO2008094939A1 (fr) 2008-08-07
US20100009015A1 (en) 2010-01-14
US20130101681A1 (en) 2013-04-25
CA2676977C (fr) 2016-10-04
US20150272991A1 (en) 2015-10-01

Similar Documents

Publication Publication Date Title
US10245325B2 (en) Methods and compositions for the sustained release of chromium
US20220023337A1 (en) Use of chromium histidinate for treatment of cardiometabolic disorders
US20050214384A1 (en) Chromium compositions and methods for using the same for inhibiting drug-induced insulin resistance
JP3699124B2 (ja) タイプｉｉ糖尿病のピコリン酸クロム高用量治療
EP2448412B1 (fr) Complexes de chromium comme activateurs de transporteurs de glucose cérébraux
WO2002076455A1 (fr) Agents de regulation autonome et poissons et aliments dietetiques
US7122209B2 (en) Oral compositions for the treatment of non-diabetic obese mammals, including humans
Nishiwaki et al. Ulcerogenic and healing impairing actions of monochloramine in rat stomachs: effects of zinc L-carnosine, polaprezinc
US8314080B2 (en) Method of treating type I diabetes

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20181024